Peptide vaccines for leishmaniasis.

Simple item page
dc.contributor.authorBrito, Rory Cristiane Fortes de
dc.contributor.authorCardoso, Jamille Mirelle de Oliveira
dc.contributor.authorReis, Levi Eduardo Soares
dc.contributor.authorVieira, João Filipe Pereira
dc.contributor.authorMathias, Fernando Augusto Siqueira
dc.contributor.authorRoatt, Bruno Mendes
dc.contributor.authorSoares, Rodrigo Dian de Oliveira Aguiar
dc.contributor.authorRuiz, Jeronimo Conceição
dc.contributor.authorResende, Daniela de Melo
dc.contributor.authorReis, Alexandre Barbosa
dc.date.accessioned2019-03-26T16:58:25Z
dc.date.available2019-03-26T16:58:25Z
dc.date.issued2018
dc.description.abstractDue to an increase in the incidence of leishmaniases worldwide, the development of new strategies such as prophylactic vaccines to prevent infection and decrease the disease have become a high priority. Classic vaccines against leishmaniases were based on live or attenuated parasites or their subunits. Nevertheless, the use of whole parasite or their subunits for vaccine production has numerous disadvantages. Therefore, the use of Leishmania peptides to design more specific vaccines against leishmaniases seems promising. Moreover, peptides have several benefits in comparison with other kinds of antigens, for instance, good stability, absence of potentially damaging materials, antigen low complexity, and low-cost to scale up. By contrast, peptides are poor immunogenic alone, and they need to be delivered correctly. In this context, several approaches described in this review are useful to solve these drawbacks. Approaches, such as, peptides in combination with potent adjuvants, cellular vaccinations, adenovirus, polyepitopes, or DNA vaccines have been used to develop peptide-based vaccines. Recent advancements in peptide vaccine design, chimeric, or polypeptide vaccines and nanovaccines based on particles attached or formulated with antigenic components or peptides have been increasingly employed to drive a specific immune response. In this review, we briefly summarize the old, current, and future stands on peptide-based vaccines, describing the disadvantages and benefits associated with them. We also propose possible approaches to overcome the related weaknesses of synthetic vaccines and suggest future guidelines for their development.pt_BR
dc.identifier.citationBRITO, R. C. F. de et al. Peptide vaccines for leishmaniasis. Frontiers in Immunology, v. 9, p. 1043, maio 2018. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958606/pdf/fimmu-09-01043.pdf>. Acesso em: 20 fev. 2019.pt_BR
dc.identifier.issn16634365
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/10828
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Fonte: o próprio artigopt_BR
dc.subjectTegumentary leishmaniasespt_BR
dc.subjectPeptide-based vaccinespt_BR
dc.subjectChimeric vaccinept_BR
dc.subjectVisceral leishmaniasispt_BR
dc.subjectPolypeptide vaccinespt_BR
dc.titlePeptide vaccines for leishmaniasis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_PeptideVaccinesLeishmaniasis.pdf
Size:
767.62 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos